Key points
- Targeting 2.2M tests across 4 key segments
- Potential total addressable market (TAM) of 5.5M tests
- Pursuing growth opportunities in high-volume labs and other segments
Full summary
Genetic Signatures Ltd, a leading provider of molecular diagnostic solutions, has released its 1H FY25 market update. The company is targeting 2.2M tests across 4 key segments, which represent 50%, 32%, 12%, and 6% of the potential total addressable market (TAM) of 5.5M tests. The high-volume LabCorp/Quest segment accounts for over 1,500 tests per day, while other segments range from 100-300 tests per day. Genetic Signatures is pursuing growth opportunities in these high-volume labs as well as in the other segments, which include GI parasite testing requirements and low to medium-volume labs. The company is leveraging its market insights and industry partnerships to drive this growth strategy and capitalize on the expanding diagnostic testing market.